Zobrazeno 1 - 10
of 41
pro vyhledávání: '"David R. Neff"'
Autor:
Salim S. Virani, Karen Aspry, Dave L. Dixon, Keith C. Ferdinand, Paul A. Heidenreich, Elizabeth J. Jackson, Terry A. Jacobson, Janice L. McAlister, David R. Neff, Martha Gulati, Christie M. Ballantyne
Publikováno v:
American Journal of Preventive Cardiology, Vol 13, Iss , Pp 100472- (2023)
Despite the established role of low-density lipoprotein cholesterol (LDL-C) as a major risk factor for cardiovascular disease (CVD), and the persistence of CVD as the leading cause of morbidity and mortality in the United States, national quality ass
Externí odkaz:
https://doaj.org/article/2d8f8ebe9f0e427090a22fcf4f5173e3
Autor:
David R. Neff, Thatcher B. Ference, John J.P. Kastelein, Brian A. Ference, Adam S. Butterworth, Clare Oliver-Williams, Stephen Burgess, Emanuele Di Angelantonio, Alberico L. Catapano, Angela M. Wood, John Danesh, Stephen J. Nicholls, Kausik K. Ray
Publikováno v:
N Engl J Med
New England journal of medicine, 380(11), 1033-1042. Massachussetts Medical Society
New England journal of medicine, 380(11), 1033-1042. Massachussetts Medical Society
BACKGROUND: ATP citrate lyase is an enzyme in the cholesterol–biosynthesis pathway upstream of 3-hydroxy-3-methylglutaryl–coenzyme A reductase (HMGCR), the target of statins. Whether the genetic inhibition of ATP citrate lyase is associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::357a5c0922cd54fa05e62528a110ec76
https://europepmc.org/articles/PMC7612927/
https://europepmc.org/articles/PMC7612927/
Autor:
David R. Neff, Adam B. Polis, Michael H. Davidson, Erin Jensen, Andrew M. Tershakovec, Joanne E. Tomassini
Publikováno v:
Data in Brief, Vol 6, Iss, Pp 530-541 (2016)
Data in Brief
Data in Brief
This brief article provides complementary data supporting the results reported in “Changing Characteristics of Statin-related cIMT Trials from 1988 to 2006” [1]. That article described time-related trends in baseline factors and study characteris
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9019d8241c75d7d4ab9ffba56432905
https://doi.org/10.1016/j.dib.2015.12.029
https://doi.org/10.1016/j.dib.2015.12.029
Autor:
Robert S. Lowe, JoAnne M. Foody, Thomas Musliner, Andrew M. Tershakovec, David R. Neff, Harry R. Davis, Peter P. Toth, Joanne E. Tomassini
Publikováno v:
Clinical Lipidology. 9:441-470
Statin therapy is highly effective in reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events; however, many high-risk patients on statin monotherapy do not achieve sufficient LDL-C lowering. Statin-dose uptitration, switching
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e0c6913d2bfad49855eb56d82ea1c0e
https://doi.org/10.2217/clp.14.36
https://doi.org/10.2217/clp.14.36
Autor:
Elizabeth Selvin, Kerry Willis, Morgan E. Grams, Meredith C. Foster, Andreea M. Rawlings, Elizabeth Marrett, David R. Neff, Lesley A. Inker, Bertram L. Kasiske, Josef Coresh
Publikováno v:
American Journal of Kidney Diseases. 63:753-760
Background Persons with chronic kidney disease (CKD) are at high risk for cardiovascular disease events, but are not classified as such in current US cholesterol treatment guidelines. We examined potential effects of modified guidelines in which CKD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e583b921c1834eca41ae85fc04b19b8
https://doi.org/10.1053/j.ajkd.2013.11.014
https://doi.org/10.1053/j.ajkd.2013.11.014
Autor:
Dena R. Ramey, Ning Jackie Zhang, David R. Neff, Andrew M. Tershakovec, Elizabeth Marrett, Qiaoyi Zhang, Changgeng Zhao, Veronica Ashton
Publikováno v:
Clinical Therapeutics. 36:792-799
Statin therapy is recommended as the first-line pharmacotherapeutic approach for lowering LDL-C levels in patients at high cardiovascular risk.To assess LDL-C levels among patients at high cardiovascular risk treated with rosuvastatin monotherapy.Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e807f18c902fb896319c197066fa71c
https://doi.org/10.1016/j.clinthera.2014.03.010
https://doi.org/10.1016/j.clinthera.2014.03.010
Autor:
Peter P. Toth, Dena R. Ramey, JoAnne M. Foody, Andrew M. Tershakovec, David R. Neff, Kaan Tunceli, Joanne E. Tomassini, Shiva Sajjan, X. Henry Hu
Publikováno v:
Journal of Clinical Lipidology. 8:107-116
Statin combination therapy and statin uptitration have been shown to be efficacious in low-density lipoprotein cholesterol (LDL-C) lowering and are recommended for patients with high-risk coronary heart disease (CHD) who do not reach guideline-endors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d93561abfebe41ca44c2667608a7727b
https://doi.org/10.1016/j.jacl.2013.09.009
https://doi.org/10.1016/j.jacl.2013.09.009
Autor:
Marc S. Sabatine, Robert D. Brook, Brian A. Ference, George Davey Smith, Sergio Fazio, Jennifer G. Robinson, Alberico L. Catapano, Szilard Voros, M. John Chapman, David R. Neff, Robert P. Giugliano
Publikováno v:
Ference, B, Robinson, J, Brook, R, Catapano, A L, Chapman, J, Neff, D, Voros, S, Giugliano, R, Davey Smith, G, Fazio, S & Sabatine, M S 2016, ' Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes ', New England Journal of Medicine, vol. 375, no. 22, pp. 2144-2153 . https://doi.org/10.1056/NEJMoa1604304
Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibitin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e25538aef9a23e32d65c6fc6d20e64c3
https://pubmed.ncbi.nlm.nih.gov/28453736
https://pubmed.ncbi.nlm.nih.gov/28453736
Autor:
Elizabeth Marrett, David R. Neff, Dena R. Ramey, Hui-Min Hsieh, Ross J. Simpson, Kaan Tunceli, Terry A. Jacobson, David M. Kern, Joanne E. Tomassini, Judith J. Stephenson, Debra A. Wertz
Publikováno v:
Journal of Clinical Lipidology. 7:399-407
For high-risk patients who do not achieve guideline-recommended LDL-C levels, more intensive treatment including statin-uptitration to higher doses or potency, as well as combination therapy may be considered. A better understanding of statin treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce7c132fa2f744d05db73fd9082ce431
https://doi.org/10.1016/j.jacl.2013.06.002
https://doi.org/10.1016/j.jacl.2013.06.002
Publikováno v:
Journal of Atherosclerosis and Thrombosis. 20:123-133
Cardiovascular disease is increased in patients with chronic kidney disease (CKD) and is the principle cause of morbidity and mortality in these patients. In patients with stage 5 CKD, structural changes in the myocardium have been implicated as the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f18c0a0b119f25d0bc7c8fb5b8b6601
https://doi.org/10.5551/jat.12849
https://doi.org/10.5551/jat.12849